Histone deacetylase inhibitors providing an epigenetic treatment in cancer
Cancer is among the leading causes of death worldwide and is therefore one of the diseases in which there have been major medical advances and which is the focus of researchers. Drugs used in cancer treatment affect rapidly proliferating normal cells as well as cancer cells. In recent years, targete...
Gespeichert in:
Veröffentlicht in: | Istanbul Journal of Pharmacy 2021-08, Vol.51 (2), p.283-8 |
---|---|
Hauptverfasser: | , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 8 |
---|---|
container_issue | 2 |
container_start_page | 283 |
container_title | Istanbul Journal of Pharmacy |
container_volume | 51 |
creator | Cinek, Tugce Karali, Nilgun |
description | Cancer is among the leading causes of death worldwide and is therefore one of the diseases in which there have been major medical advances and which is the focus of researchers. Drugs used in cancer treatment affect rapidly proliferating normal cells as well as cancer cells. In recent years, targeted therapy has been provided by identifying specific pathways in cancer cells. Epigenetic mechanisms are among the targeted therapies in cancer treatment. Epigenetic regulators ensure the continuity of the normal process by inducing epigenetic changes through epigenetic mechanisms such as DNA methylation, histone post-translational modifications, and non-coding RNA regulation. Histone deacetylases (HDACs), which are involved in transcription-independent events such as DNA repair and mitosis, are enzymes that remove acetyl groups attached to the lysine residue in the amino terminal tails of histones. Histone deacetylase inhibitors (HDACIs) that provide epigenetic treatment of cancer, which play a key role in the balance between acetylation and deacetylation of histone, have been extensively studied by researchers. Today, there are four HDACIs on the market approved by the FDA (Food and Drug Administration) and combinations of these drugs with agents that show anticancer activity by different mechanisms are being studied. Promising results have been obtained from these combinations, and further studies are ongoing on hybrid derivatives of certain HDACIs in various stages. Keywords: Cancer, epigenetic mechanisms, histone deacetylase, histone deacetylase inhibitors |
doi_str_mv | 10.26650/IstanbulJPharm.2021.904686 |
format | Article |
fullrecord | <record><control><sourceid>gale_ideal</sourceid><recordid>TN_cdi_idealonline_journals_IDEAL_154812</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A679082793</galeid><sourcerecordid>A679082793</sourcerecordid><originalsourceid>FETCH-LOGICAL-c357t-d6c62b28185b4f205f847254a6e5763fa5fbbd6f38b34c5b5a37b67cbedfa793</originalsourceid><addsrcrecordid>eNqNkU1LAzEQhhdRULT_YaEXL12T7OajeCp-tVLQg_eQZCdtym62JFHw3xtdQQVBmcMMwzPvDPMWxRSjijBG0cUqJuX1c3f_uFWhrwgiuJqjhgl2UJwQKviMIMEPv9XHxSTGHUKIUIwFrk-K-6WLafBQtqAMpNdORSid3zrt0hBiuQ_Di2ud35TKl7B3G_CQnClTAJV68CnDpVHeQDgrjqzqIkw-82nxdHvzdLWcrR_uVleL9czUlKdZywwjmggsqG4sQdSKhhPaKAaUs9oqarVuma2FrhtDNVU114wbDa1VfF6fFuejrMsnd4PvnAe5G56Dz0vl6vpmsZaYNgKTjE5HdKM6kM7bIQVleheNXDA-R4JkvT8ojjGmmGaq-oXK0ULvTP6gdbn_Q_afA18bLscBE4YYA1i5D65X4VViJD8clz8dl--Oy9Hx-g3ioqFX</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Histone deacetylase inhibitors providing an epigenetic treatment in cancer</title><source>Alma/SFX Local Collection</source><creator>Cinek, Tugce ; Karali, Nilgun</creator><contributor>Özsoy Erginer,Yıldız ; Akalın Uruşak,Emine ; Karalı,Nilgün</contributor><creatorcontrib>Cinek, Tugce ; Karali, Nilgun ; Özsoy Erginer,Yıldız ; Akalın Uruşak,Emine ; Karalı,Nilgün</creatorcontrib><description>Cancer is among the leading causes of death worldwide and is therefore one of the diseases in which there have been major medical advances and which is the focus of researchers. Drugs used in cancer treatment affect rapidly proliferating normal cells as well as cancer cells. In recent years, targeted therapy has been provided by identifying specific pathways in cancer cells. Epigenetic mechanisms are among the targeted therapies in cancer treatment. Epigenetic regulators ensure the continuity of the normal process by inducing epigenetic changes through epigenetic mechanisms such as DNA methylation, histone post-translational modifications, and non-coding RNA regulation. Histone deacetylases (HDACs), which are involved in transcription-independent events such as DNA repair and mitosis, are enzymes that remove acetyl groups attached to the lysine residue in the amino terminal tails of histones. Histone deacetylase inhibitors (HDACIs) that provide epigenetic treatment of cancer, which play a key role in the balance between acetylation and deacetylation of histone, have been extensively studied by researchers. Today, there are four HDACIs on the market approved by the FDA (Food and Drug Administration) and combinations of these drugs with agents that show anticancer activity by different mechanisms are being studied. Promising results have been obtained from these combinations, and further studies are ongoing on hybrid derivatives of certain HDACIs in various stages. Keywords: Cancer, epigenetic mechanisms, histone deacetylase, histone deacetylase inhibitors</description><identifier>ISSN: 2587-2087</identifier><identifier>ISSN: 2548-0731</identifier><identifier>EISSN: 2587-2087</identifier><identifier>DOI: 10.26650/IstanbulJPharm.2021.904686</identifier><language>eng</language><publisher>AVES</publisher><subject>Acetates ; Antimitotic agents ; Antineoplastic agents ; Cancer ; Care and treatment ; DNA binding proteins ; Drug approval ; Drug therapy ; Eczacılık ; Epigenetic inheritance ; Genetic transcription ; Health aspects ; Lysine ; Methylation ; RNA ; Tıp</subject><ispartof>Istanbul Journal of Pharmacy, 2021-08, Vol.51 (2), p.283-8</ispartof><rights>COPYRIGHT 2021 AVES</rights><rights>COPYRIGHT 2021 Istanbul University Press</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><contributor>Özsoy Erginer,Yıldız</contributor><contributor>Akalın Uruşak,Emine</contributor><contributor>Karalı,Nilgün</contributor><creatorcontrib>Cinek, Tugce</creatorcontrib><creatorcontrib>Karali, Nilgun</creatorcontrib><title>Histone deacetylase inhibitors providing an epigenetic treatment in cancer</title><title>Istanbul Journal of Pharmacy</title><description>Cancer is among the leading causes of death worldwide and is therefore one of the diseases in which there have been major medical advances and which is the focus of researchers. Drugs used in cancer treatment affect rapidly proliferating normal cells as well as cancer cells. In recent years, targeted therapy has been provided by identifying specific pathways in cancer cells. Epigenetic mechanisms are among the targeted therapies in cancer treatment. Epigenetic regulators ensure the continuity of the normal process by inducing epigenetic changes through epigenetic mechanisms such as DNA methylation, histone post-translational modifications, and non-coding RNA regulation. Histone deacetylases (HDACs), which are involved in transcription-independent events such as DNA repair and mitosis, are enzymes that remove acetyl groups attached to the lysine residue in the amino terminal tails of histones. Histone deacetylase inhibitors (HDACIs) that provide epigenetic treatment of cancer, which play a key role in the balance between acetylation and deacetylation of histone, have been extensively studied by researchers. Today, there are four HDACIs on the market approved by the FDA (Food and Drug Administration) and combinations of these drugs with agents that show anticancer activity by different mechanisms are being studied. Promising results have been obtained from these combinations, and further studies are ongoing on hybrid derivatives of certain HDACIs in various stages. Keywords: Cancer, epigenetic mechanisms, histone deacetylase, histone deacetylase inhibitors</description><subject>Acetates</subject><subject>Antimitotic agents</subject><subject>Antineoplastic agents</subject><subject>Cancer</subject><subject>Care and treatment</subject><subject>DNA binding proteins</subject><subject>Drug approval</subject><subject>Drug therapy</subject><subject>Eczacılık</subject><subject>Epigenetic inheritance</subject><subject>Genetic transcription</subject><subject>Health aspects</subject><subject>Lysine</subject><subject>Methylation</subject><subject>RNA</subject><subject>Tıp</subject><issn>2587-2087</issn><issn>2548-0731</issn><issn>2587-2087</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNqNkU1LAzEQhhdRULT_YaEXL12T7OajeCp-tVLQg_eQZCdtym62JFHw3xtdQQVBmcMMwzPvDPMWxRSjijBG0cUqJuX1c3f_uFWhrwgiuJqjhgl2UJwQKviMIMEPv9XHxSTGHUKIUIwFrk-K-6WLafBQtqAMpNdORSid3zrt0hBiuQ_Di2ud35TKl7B3G_CQnClTAJV68CnDpVHeQDgrjqzqIkw-82nxdHvzdLWcrR_uVleL9czUlKdZywwjmggsqG4sQdSKhhPaKAaUs9oqarVuma2FrhtDNVU114wbDa1VfF6fFuejrMsnd4PvnAe5G56Dz0vl6vpmsZaYNgKTjE5HdKM6kM7bIQVleheNXDA-R4JkvT8ojjGmmGaq-oXK0ULvTP6gdbn_Q_afA18bLscBE4YYA1i5D65X4VViJD8clz8dl--Oy9Hx-g3ioqFX</recordid><startdate>20210801</startdate><enddate>20210801</enddate><creator>Cinek, Tugce</creator><creator>Karali, Nilgun</creator><general>AVES</general><general>Istanbul University Press</general><general>İstanbul Üniversitesi Yayınları</general><scope>AAYXX</scope><scope>CITATION</scope><scope>IEBAR</scope></search><sort><creationdate>20210801</creationdate><title>Histone deacetylase inhibitors providing an epigenetic treatment in cancer</title><author>Cinek, Tugce ; Karali, Nilgun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c357t-d6c62b28185b4f205f847254a6e5763fa5fbbd6f38b34c5b5a37b67cbedfa793</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Acetates</topic><topic>Antimitotic agents</topic><topic>Antineoplastic agents</topic><topic>Cancer</topic><topic>Care and treatment</topic><topic>DNA binding proteins</topic><topic>Drug approval</topic><topic>Drug therapy</topic><topic>Eczacılık</topic><topic>Epigenetic inheritance</topic><topic>Genetic transcription</topic><topic>Health aspects</topic><topic>Lysine</topic><topic>Methylation</topic><topic>RNA</topic><topic>Tıp</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cinek, Tugce</creatorcontrib><creatorcontrib>Karali, Nilgun</creatorcontrib><collection>CrossRef</collection><collection>Idealonline online kütüphane - Journals</collection><jtitle>Istanbul Journal of Pharmacy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cinek, Tugce</au><au>Karali, Nilgun</au><au>Özsoy Erginer,Yıldız</au><au>Akalın Uruşak,Emine</au><au>Karalı,Nilgün</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Histone deacetylase inhibitors providing an epigenetic treatment in cancer</atitle><jtitle>Istanbul Journal of Pharmacy</jtitle><date>2021-08-01</date><risdate>2021</risdate><volume>51</volume><issue>2</issue><spage>283</spage><epage>8</epage><pages>283-8</pages><issn>2587-2087</issn><issn>2548-0731</issn><eissn>2587-2087</eissn><abstract>Cancer is among the leading causes of death worldwide and is therefore one of the diseases in which there have been major medical advances and which is the focus of researchers. Drugs used in cancer treatment affect rapidly proliferating normal cells as well as cancer cells. In recent years, targeted therapy has been provided by identifying specific pathways in cancer cells. Epigenetic mechanisms are among the targeted therapies in cancer treatment. Epigenetic regulators ensure the continuity of the normal process by inducing epigenetic changes through epigenetic mechanisms such as DNA methylation, histone post-translational modifications, and non-coding RNA regulation. Histone deacetylases (HDACs), which are involved in transcription-independent events such as DNA repair and mitosis, are enzymes that remove acetyl groups attached to the lysine residue in the amino terminal tails of histones. Histone deacetylase inhibitors (HDACIs) that provide epigenetic treatment of cancer, which play a key role in the balance between acetylation and deacetylation of histone, have been extensively studied by researchers. Today, there are four HDACIs on the market approved by the FDA (Food and Drug Administration) and combinations of these drugs with agents that show anticancer activity by different mechanisms are being studied. Promising results have been obtained from these combinations, and further studies are ongoing on hybrid derivatives of certain HDACIs in various stages. Keywords: Cancer, epigenetic mechanisms, histone deacetylase, histone deacetylase inhibitors</abstract><pub>AVES</pub><doi>10.26650/IstanbulJPharm.2021.904686</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2587-2087 |
ispartof | Istanbul Journal of Pharmacy, 2021-08, Vol.51 (2), p.283-8 |
issn | 2587-2087 2548-0731 2587-2087 |
language | eng |
recordid | cdi_idealonline_journals_IDEAL_154812 |
source | Alma/SFX Local Collection |
subjects | Acetates Antimitotic agents Antineoplastic agents Cancer Care and treatment DNA binding proteins Drug approval Drug therapy Eczacılık Epigenetic inheritance Genetic transcription Health aspects Lysine Methylation RNA Tıp |
title | Histone deacetylase inhibitors providing an epigenetic treatment in cancer |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T14%3A17%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_ideal&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Histone%20deacetylase%20inhibitors%20providing%20an%20epigenetic%20treatment%20in%20cancer&rft.jtitle=Istanbul%20Journal%20of%20Pharmacy&rft.au=Cinek,%20Tugce&rft.date=2021-08-01&rft.volume=51&rft.issue=2&rft.spage=283&rft.epage=8&rft.pages=283-8&rft.issn=2587-2087&rft.eissn=2587-2087&rft_id=info:doi/10.26650/IstanbulJPharm.2021.904686&rft_dat=%3Cgale_ideal%3EA679082793%3C/gale_ideal%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_galeid=A679082793&rfr_iscdi=true |